Agenus (AGEN) to Acquire XOMA's (XOMA) Biologics Manufacturing Facilities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
XOMA (XOMA) Uses License Deals and Restructuring to Extend Runway to 2017; Piper Jaffray Remains Neutral
November 6, 2015 10:35 AM ESTPiper Jaffray reiterated a Neutral rating on XOMA, Ltd. (NASDAQ: XOMA), and raised the price target to $1.80 (from $1.50), following the company's 3Q earnings report. XOMA ended 3Q:15 with $32 million. The company subsequently received $37 million from Novartis for TGF-beta upfront and $5 million from Agenus for an... More
XOMA (XOMA) Tops Q3 EPS by 16c
November 5, 2015 4:02 PM ESTXOMA (NASDAQ: XOMA) reported Q3 EPS of $0.00, $0.16 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $3.55 million.
For earnings history and earnings-related data on XOMA (XOMA) click here.
... More